Kira is an experienced courtroom lawyer who assists life sciences companies in high-stakes patent litigation.
Kira is the head of Morrison Foerster’s Los Angeles Litigation Department, a partner in the IP Litigation Group, and a member of the firm-wide Life Sciences + Healthcare Leadership Team. She regularly serves as counsel in intellectual property lawsuits involving cutting-edge technology, including foundational antibody technology, antibody cancer immunotherapies, fusion proteins, small-molecule therapeutics, transcatheter heart valve repair and replacement devices, and genetic testing and genomics technology. Kira litigates on behalf of both patentees and defendants and has significant experience representing innovators in disputes arising out of proposed generic and biosimilar launches.
Kira has been recognized by a number of regional and national publications, including as a Litigator of the Week by The American Lawyer. In 2023, she was named a Top Healthcare Lawyer by the Daily Journal.
Kira’s approach is to gain a deep understanding not only of the technology at issue, but also of her clients’ business objectives and goals, and to work closely with her clients to build litigation and pre-litigation strategies that match those goals. As a trial lawyer, Kira is known for her levelheaded and trustworthy style, allowing client witnesses to shine through on direct examination and cutting through the noise on cross-examination.
In addition to U.S. district court litigation, Kira regularly advises clients on proceedings before the Patent Trial and Appeal Board, both in matters with co-pending litigation and in stand-alone PTAB proceedings. She also often coordinates global patent litigation strategy across multiple jurisdictions, including England, Ireland, Germany, and Switzerland.
Kira also has experience representing clients in connection with other types of litigation and investigative matters, including antitrust litigation, contract disputes, white-collar criminal matters, complex commercial disputes, sports-related matters, and internal investigations.
Kira began her legal career as a law clerk to the Honorable John M. Rogers in the United States Court of Appeals for the Sixth Circuit. Prior to joining the firm, Kira was a partner at Durie Tangri, a premier litigation boutique. Kira has been active in several professional societies, including LAIPLA’s Women in IP Committee. She currently serves as a board member for The Morrison Foerster Foundation.
Kira received her J.D. summa cum laude from Cornell Law School. She received her B.A. in classics from Ohio Wesleyan University.
She is admitted to practice in California and New York.
Pharmaceutical company
Secured an important win at summary judgment in defense of a leading pharmaceutical company in a patent infringement suit brought against its innovative cancer products.
R&D company in patent litigation
Representing an R&D company in patent litigation regarding the company’s patents developed in connection with research on treatments for viral diseases.
Biopharmaceutical company
Representing a small biopharmaceutical company in its efforts to bring to market an innovative small-molecule therapeutic offering significant advantages to patients over prior treatments in the face of patent litigation filed by a competitor.
Biotechnology company
Representing a global innovative biotechnology company in PTAB proceedings brought against the company’s patents on novel combination therapies.
Bio-Rad Laboratories, Inc., et al. v. Dropworks, Inc.
(District of Delaware). Defended Dropworks, a digital PCR start-up, in patent litigation brought by Bio-Rad.
10x Genomics, Inc. v. Celsee, Inc.
(District of Delaware). Represented 10x Genomics, a life sciences technology company and a worldwide leader in genomics, in a patent infringement suit against Celsee.
Abbott Cardiovascular Systems, Inc., et al. v. Edwards Lifesciences Corp. et al.
(District of Delaware). Defended Edwards Lifesciences in a patent infringement action relating to Edwards’ PASCAL device, a novel transcatheter treatment option for mitral and tricuspid regurgitation.
Bristol-Myers Squibb Co., et al. v. Genentech, Inc.
(District of Delaware). Defended Genentech in patent infringement litigation brought against its cancer treatment Tecentriq®, the first anti-PD-L1 antibody approved to treat cancer.
Vanda Pharmaceuticals Inc. v. Roxane Labs. Inc.
(District of Delaware, Federal Circuit, and Supreme Court). Represented Vanda in Hatch-Waxman litigation regarding proposed generic versions of Vanda’s FANAPT® product. Obtained a victory at trial that was affirmed on appeal in a widely-cited opinion.
Cabilly Patent Litigations for Genentech and City of Hope
(C.D. Cal.). Represented Genentech and City of Hope in a series of challenges brought against their ground-breaking “Cabilly” patents, which covered the foundational method of manufacturing monoclonal antibodies.
Recommended for Intellectual Property: Patents: Licensing
Legal 500 2024
California Litigation Star, Intellectual Property
Benchmark Litigation 2023-2025
US (National) Litigation Star, Intellectual Property and Commercial
Benchmark Litigation 2023, 2025
Top Healthcare Lawyers
Daily Journal 2023
IP Star - Patent
Managing IP, 2022-2024